

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: MARK W. SLEEMAN ET AL.

Serial No.: to be assigned **Group:** to be assigned

Filing Date: Concurrently Herewith **Examiner:** to be assigned

Title: METHODS OF TREATING DIABETES BY BLOCKING VEGF-MEDIATED ACTIVITY

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56 and 1.97**

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450.

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449. The PTO is kindly requested to make of record those references which may be pertinent to the examination of the above-referenced application.

This Information Disclosure Statement is being filed:

- [X] (b) Within three months of the filing date of the above referenced application; within three months of the entry of an international application into the national phase; before the mailing date of a first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, no fee is required for the submission.

Docket No.: REG 711A
Sleeman et al.
IDS Transmittal

Fees

No fee is required for the filing of this Information Disclosure Statement. If any additional fee should be deemed necessary, the Commissioner is hereby authorized to charge Deposit Account Number 18-0650.

Respectfully submitted



Valeta Gregg

Reg. No. 35,127

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, New York 10591

(914) 345-7400

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att. Docket No. : REG 711A
Serial No. : Not Yet Known
Applicant: : Mark W. Sleeman et al.
Date Filed : Concurrently Herewith
For : Methods for Treating Diabetes by
Blocking VEGF-Mediated Activity
Examiner : Not Yet Known
Group Art Unit : Not Yet Known

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

U.S. PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Patent Date</u>	<u>Name</u>	<u>Class/ Subclass</u>	<u>Filing Date</u>
_____	_____	_____	_____	_____	_____

FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/ Subclass</u>	<u>Translation Yes No</u>
_____	_____	_____	_____	_____	_____

OTHER DOCUMENTS

**Examiner
Initials**

- _____ De Vriese, A., et al., 2001, "Antibodies Against Vascular Endothelial Growth Factor Improve Early Renal Dysfunction in Experiment Diabetes", J. Am. Soc. Nephrol. 12:993-1000.
- _____ Ereemina, V., et al., 2003, "Glomerular-Specific Alterations of VEGF-A Expression Lead to Distinct Congenital and Acquired Renal Diseases", J. Clin. Invest. 111:707-716.
- _____ Cooper, M., et al., 1999, "Increased Renal Expression of Vascular Endothelial Growth Factor (VEGF) and Its Receptor VEGFR-2 in Experimental Diabetes", Diabetes, 48:2229-2239.
- _____ Flyvbjerg, A., et al., 2002, "Amelioration of Long-Term Renal Changes in Obese Type 2 Diabetic Mice by a Neutralizing Vascular Endothelial Growth Factor Antibody", Diabetes, 51:3090-3094.

**EXAMINER
CONSIDERED**

DATE


EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

REG 711A
USSN Not Yet Known
PTO 1449 Form
Sleeman et al.
Page 3

By:


Valeta Gregg
Reg. No. 35,127
Attorneys for Applicant
Patent Agent for Applicant
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400